Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abingdon Life Sciences, Inc.
Abingdon Life Sciences, Inc. Enters Into Strategic Alliance With Stason Pharmaceuticals, Inc. to Provide Regulatory and Clinical Support
August 22nd, 2008
Abingdon Life Sciences, Inc. has entered into an agreement with Stason Pharmaceuticals, Inc. to provide clinical and regulatory support for Stason's drug development programs. As part of the agreement, Abingdon will provide clinical and regulatory services for Stason's pipeline of potential drug candidates and devices in the areas of cancer and inflammation. "We are extremely happy to have formalized our relationship with Stason, and believe that this represents a synergistic opportunity for both our companies to leverage our respective core competencies in drug development and manufacturing," said Richard Lebovitz, Abingdon CEO. Harry Fan, CEO of Stason added, "Stason...
Source: Health Business Week (2008-08-22)
|
